{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:15:56Z","timestamp":1791375356820,"version":"4.3.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinthera.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:34:01Z","timestamp":1739939641000},"page":"252-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Thalidomide on Metabolism and Lifespan of Red Blood Cell in Patients With \u03b2-Thalassemia Major: A Post Hoc Analysis of a Randomized Controlled Trial"],"prefix":"10.1016","volume":"47","author":[{"given":"Huanju","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5371-802X","authenticated-orcid":false,"given":"Sichong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8503-9464","authenticated-orcid":false,"given":"Lujie","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangdong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-843X","authenticated-orcid":false,"given":"Zhengwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.01.008_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0002","first-page":"339","article-title":"Alpha and beta thalassemia","volume":"80","author":"Muncie","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0003","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2010-08-300335","article-title":"How I treat thalassemia","volume":"118","author":"Rachmilewitz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0004","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3949\/ccjm.74.11.807","article-title":"Getting the iron out: preventing and treating heart failure in transfusion-dependent thalassemia","volume":"74","author":"Jabbar","year":"2007","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0007","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2012-10-408021","article-title":"Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia","volume":"121","author":"Musallam","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0008","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0009","first-page":"86","article-title":"Clinical application of recombinant erythropoietin in beta-thalassaemia intermedia","volume":"255","author":"Asadov","year":"2016","journal-title":"Georgian Med News"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0010","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.021","article-title":"Thalidomide for patients with beta-thalassemia: a multicenter experience","volume":"12","author":"Yang","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0011","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s00277-014-2154-5","article-title":"Response to hydroxycarbamide in pediatric beta-thalassemia intermedia: 8 years\u2019 follow-up in Egypt","volume":"93","author":"El-Beshlawy","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12185-011-0985-6","article-title":"Genotype-phenotype relationship of patients with beta-thalassemia taking hydroxyurea: a 13-year experience in Iran","volume":"95","author":"Karimi","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0013","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2141.2010.08397.x","article-title":"Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients","volume":"151","author":"Rigano","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0014","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2141.2006.06002.x","article-title":"Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up","volume":"133","author":"Mancuso","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0015","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/08880010903271671","article-title":"Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature","volume":"26","author":"Ehsani","year":"2009","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0016","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1249543","article-title":"Medicine. How thalidomide works against cancer","volume":"343","author":"Stewart","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0017","first-page":"37","article-title":"Thalidomide is more efficient than sodium butyrate in enhancing GATA-1 and EKLF gene expression in erythroid progenitors derived from HSCs with beta-globin gene mutation","volume":"10","author":"Jalali Far","year":"2016","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0018","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2007-01-065201","article-title":"Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis","volume":"110","author":"Aerbajinai","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0019","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.24030","article-title":"Dramatic erythroid response to low-dose thalidomide in two patients with transfusion independent thalassemia and severe post-transfusional alloimmune hemolysis","volume":"90","author":"Fozza","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcmd.2016.01.003","article-title":"The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with non-transfusion-dependent thalassemia","volume":"57","author":"Ricchi","year":"2016","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12955","article-title":"Thalidomide induces haematologic responses in patients with beta-thalassaemia","volume":"99","author":"Chen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0022","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/10245332.2017.1354427","article-title":"Thalidomide has a significant effect in patients with thalassemia intermedia","volume":"23","author":"Li","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2008.03.001","article-title":"Thalidomide therapy in a patient with thalassemia major","volume":"41","author":"Aguilar-Lopez","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0024","first-page":"63","article-title":"Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy","volume":"8","author":"Masera","year":"2010","journal-title":"Blood Transfus"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0025","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00277-018-3395-5","article-title":"Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia","volume":"97","author":"Ren","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41392-021-00811-0","article-title":"Safety and efficacy of thalidomide in patients with transfusion-dependent beta-thalassemia: a randomized clinical trial","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0027","series-title":"Histology: Red Blood Cell","author":"Barbalato","year":"2022"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0028","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1081\/IPH-200042279","article-title":"Stabilization of red blood cell membranes by thalidomide in vitro","volume":"26","author":"Tadesse","year":"2004","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0029","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.3390\/jcm9113782","article-title":"Fetal hemoglobin in sickle hemoglobinopathies: high HbF genotypes and phenotypes","volume":"9","author":"Steinberg","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.5539\/gjhs.v8n3p252","article-title":"Hydroxyurea: clinical and hematological effects in patients with sickle cell anemia","volume":"8","author":"Keikhaei","year":"2015","journal-title":"Glob J Health Sci"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0031","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1590\/S0100-879X1997000800004","article-title":"Minimal doses of hydroxyurea for sickle cell disease","volume":"30","author":"Lima","year":"1997","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0032","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.V66.3.527.527","article-title":"5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens","volume":"66","author":"Dover","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0033","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1097\/HS9.0000000000000584","article-title":"Research in sickle cell disease: from bedside to bench to bedside","volume":"5","author":"Salinas Cisneros","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0034","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.pharep.2015.05.011","article-title":"Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor","volume":"67","author":"Grzasko","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1399-0004.2010.01430.x","article-title":"Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China","volume":"78","author":"Xiong","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0036","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/pbc.23101","article-title":"Treatment and complications of thalassemia major in Guangxi, Southern China","volume":"57","author":"Yin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0037","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.029","article-title":"Thyroid disorders in homozygous beta-thalassemia: current knowledge, emerging issues and open problems","volume":"11","author":"De Sanctis","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0038","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2019.036","article-title":"Economic evaluation of chelation regimens for beta-thalassemia major: a systematic review","volume":"11","author":"Li","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0039","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0040","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0041","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: a comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0042","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1172\/JCI32322","article-title":"Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells","volume":"118","author":"Moutouh-de Parseval","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0043","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-11-319137","article-title":"Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice","volume":"118","author":"Meiler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2025.01.008_bib0044","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/blood-2015-09-667923","article-title":"Pomalidomide reverses gamma-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors","volume":"127","author":"Dulmovits","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:22:26Z","timestamp":1741684946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0149291825000098"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Thalidomide on Metabolism and Lifespan of Red Blood Cell in Patients With \u03b2-Thalassemia Major: A Post Hoc Analysis of a Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}